ClinicalTrials.gov
public full text
Public Domain
The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children
Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus#1362984
- The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus#1044330
- Brain Dopamine Biomarker#901655
- The GABAergic Inhibitory System in Drug Resistant Epilepsy#1228286
- A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)#801285
Record · ID 1339837
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive